Section 1 MAD examine might be carried out to judge the security, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) traits of ID110521156 following repeated administration and stepwise improve in dose.
Beforehand, Yunovia not solely confirmed the drug’s effectiveness associated to insulin secretion and blood glucose management, but additionally, its superior tolerability in comparison with different medicine in the identical class by way of preclinical efficacy and toxicity evaluations within the lately accomplished Section 1 SAD examine.
ID110521156 is a GLP-1 (glucagon-like peptide-1) receptor agonist that performs the identical function because the GLP-1 hormone which is concerned within the synthesis and secretion of insulin within the physique, discount of blood glucose degree, regulation of gastrointestinal tract actions, and urge for food suppression.
Since ID110521156 is a small molecule compound, the Firm’s technique is to develop it as an orally administrable drug for diabetes and weight problems with differentiated attributes equivalent to superior manufacturability and ease of use in comparison with peptide injections, the present customary of care.
A Yunovia consultant emphasised, “ID110521156 is the only small molecule based new drug in the clinical stage among all GLP-1 receptor agonists in
The Firm consultant additional said, “We had been communicating with potential partner companies from the early development stage where their feedback from the perspective of the needs of the ‘GLP-1 market’, had been reflected in the designing of the SAD and MAD studies” Primarily based on our persevering with dialogue with them, we are going to proceed with additional improvement of ID110521156 and, pursue international out-licensing.
About ID110521156
ID110521156 is an orally obtainable small molecule agonist of the GLP-1 receptor. Yunovia accomplished its Section I SAD, together with meals impact examine, in
About Yunovia
Yunovia was established in 2023 as a split-off from Ildong pharmaceutical to launch the total potential worth of worldwide, modern drug pipeline and to maximise the R&D productiveness for accelerated drug improvement. Yunovia’s R&D pipeline contains greater than 20 modern applications at varied improvement phases for varied therapeutic areas. With its small molecule R&D experience and pipeline, together with 3+ medical applications, Yunovia will attempt to develop as a number one innovator for all times altering therapeutics. For extra data, please go to https://www.yunovia.com/eng/primary/.
CONTACT:
